Iranian Red Crescent Medical Journal

Published by: Kowsar

Comparison of Anticancer Effects of Carbamazepine and Valproic Acid

Ladan Akbarzadeh 1 , * , Taraneh Moini Zanjani 1 and Masoumeh Sabetkasaei 1
Authors Information
1 Department of Pharmacology, Shahid Beheshti University, Tehran, IR Iran
Article information
  • Iranian Red Crescent Medical Journal: October 01, 2016, 18 (10); e37230
  • Published Online: August 4, 2016
  • Article Type: Research Article
  • Received: February 19, 2016
  • Revised: May 22, 2016
  • Accepted: June 14, 2016
  • DOI: 10.5812/ircmj.37230

To Cite: Akbarzadeh L, Moini Zanjani T, Sabetkasaei M. Comparison of Anticancer Effects of Carbamazepine and Valproic Acid, Iran Red Crescent Med J. 2016 ; 18(10):e37230. doi: 10.5812/ircmj.37230.

Copyright © 2016, Iranian Red Crescent Medical Journal. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. McNamara JO. Drugs effective in the therapy of the epilepsies. 2011; : 583-607
  • 2. Marks PA, Richon VM, Breslow R, Rifkind RA. Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol. 2001; 13(6): 477-83[PubMed]
  • 3. Kramer OH, Gottlicher M, Heinzel T. Histone deacetylase as a therapeutic target. Trends Endocrinol Metab. 2001; 12(7): 294-300[PubMed]
  • 4. Sandor V. Phase I trial of the histone deacetylase inhibitor, depsipeptide in refractory neoplasms. Cancer Res. 2002; 8(3): 718-28
  • 5. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer. 2001; 1(3): 194-202[DOI][PubMed]
  • 6. Blaheta RA, Michaelis M, Driever PH, Cinatl J. Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies. Med Res Rev. 2005; 25(4): 383-97[DOI][PubMed]
  • 7. Beutler AS, Li S, Nicol R, Walsh MJ. Carbamazepine is an inhibitor of histone deacetylases. Life Sci. 2005; 76(26): 3107-15[DOI][PubMed]
  • 8. Nanau RM, Neuman MG. Adverse drug reactions induced by valproic acid. Clin Biochem. 2013; 46(15): 1323-38[DOI][PubMed]
  • 9. Xu R, Zhou B, Fung PC, Li X. Recent advances in the treatment of colon cancer. Histol Histopathol. 2006; 21(8): 867-72[PubMed]
  • 10. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61(2): 69-90[DOI][PubMed]
  • 11. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell. 2006; 127(3): 469-80[DOI][PubMed]
  • 12. Khalil S, Tan GA, Giri DD, Zhou XK, Howe LR. Activation status of Wnt/ss-catenin signaling in normal and neoplastic breast tissues: relationship to HER2/neu expression in human and mouse. PLoS One. 2012; 7(3): 33421[DOI][PubMed]
  • 13. Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene. 2007; 26(37): 5420-32[DOI][PubMed]
  • 14. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene. 2007; 26(37): 5541-52[DOI][PubMed]
  • 15. Takai N, Desmond JC, Kumagai T, Gui D, Said JW, Whittaker S, et al. Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clin Cancer Res. 2004; 10(3): 1141-9[PubMed]
  • 16. Glaser KB. Gene expression histone deacetylase inhibitors in T24 and MDA cell lines. Cancer Ther. 2003; 2(2): 151-63
  • 17. Gray SG, Qian CN, Furge K, Guo X, Teh BT. Microarray profiling of the effects of histone deacetylase inhibitors on gene expression in cancer cell lines. Int J Oncol. 2004; 24(4): 773-95[PubMed]
  • 18. de Ruijter AJ, Meinsma RJ, Bosma P, Kemp S, Caron HN, van Kuilenburg AB. Gene expression profiling in response to the histone deacetylase inhibitor BL1521 in neuroblastoma. Exp Cell Res. 2005; 309(2): 451-67[DOI][PubMed]
  • 19. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem. 2001; 276(39): 36734-41[DOI][PubMed]
  • 20. Loscher W. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs. 2002; 16(10): 669-94[PubMed]
  • 21. Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 2001; 20(24): 6969-78[DOI][PubMed]
  • 22. Blaheta RA, Cinatl J. Anti-tumor mechanisms of valproate: a novel role for an old drug. Med Res Rev. 2002; 22(5): 492-511[DOI][PubMed]
  • 23. Stettner M, Kramer G, Strauss A, Kvitkina T, Ohle S, Kieseier BC, et al. Long-term antiepileptic treatment with histone deacetylase inhibitors may reduce the risk of prostate cancer. Eur J Cancer Prev. 2012; 21(1): 55-64[DOI][PubMed]
  • 24. Hoti N, Chowdhury W, Hsieh JT, Sachs MD, Lupold SE, Rodriguez R. Valproic acid, a histone deacetylase inhibitor, is an antagonist for oncolytic adenoviral gene therapy. Mol Ther. 2006; 14(6): 768-78[DOI][PubMed]
  • 25. Kutko MC. Histone deacetylase 8 inhibitors induce growth suppression in human rhabdomyosarcoma in vitro. Cancer Res. 2003; 9(15): 5749-55
  • 26. Sawa H, Murakami H, Ohshima Y, Sugino T, Nakajyo T, Kisanuki T, et al. Histone deacetylase inhibitors such as sodium butyrate and trichostatin A induce apoptosis through an increase of the bcl-2-related protein Bad. Brain Tumor Pathol. 2001; 18(2): 109-14[PubMed]
  • 27. Li GC, Zhang X, Pan TJ, Chen Z, Ye ZQ. Histone deacetylase inhibitor trichostatin A inhibits the growth of bladder cancer cells through induction of p21WAF1 and G1 cell cycle arrest. Int J Urol. 2006; 13(5): 581-6[DOI][PubMed]
  • 28. Peifer M, Polakis P. Wnt signaling in oncogenesis and embryogenesis--a look outside the nucleus. Science. 2000; 287(5458): 1606-9[PubMed]
  • 29. Deroanne CF, Bonjean K, Servotte S, Devy L, Colige A, Clausse N, et al. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene. 2002; 21(3): 427-36[DOI][PubMed]
  • 30. Kim MS, Kwon HJ, Lee YM, Baek JH, Jang JE, Lee SW, et al. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med. 2001; 7(4): 437-43[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments